Implants maker Zimmer Biomet beats Q3 adjusted EPS expectations on US driven growth

Zimmer Biomet Holdings

05/11/2025 11:43

Corrects Overview section and Key Details table to show revenue met, not missed, analysts expectations

Overview

Zimmer Biomet Q3 net sales rose 9.7%, meeting analyst expectations

Adjusted EPS for Q3 beats consensus, increasing by 9.2%

Company's U.S. growth driven by new product adoption, offset by regional weaknesses

Outlook

Zimmer Biomet maintains full-year revenue growth guidance at 6.7% to 7.7%

Company narrows full-year constant currency revenue growth to 6.2% to 6.7%

Zimmer Biomet projects full-year adjusted EPS between $8.10 and $8.30

Result Drivers

U.S. GROWTH - 5.6% organic revenue growth in U.S. driven by adoption of new products, per CEO Ivan Tornos

REGIONAL WEAKNESS - Performance offset by weakness in Latin America, Emerging Markets in Europe, and non-core businesses

NEW TECHNOLOGIES - Upcoming launch of iodine-treated hip implant and autonomous robot expected to drive growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Meet
$2 bln
$2 bln (22 Analysts)
Q3 Adjusted EPS
Beat
$1.90
$1.86 (24 Analysts)
Q3 EPS
$1.16
Q3 Net Income
$230.90 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 11 "strong buy" or "buy", 17 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Zimmer Biomet Holdings Inc is $108.00, about 4.5% above its November 4 closing price of $103.18

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nPn3PrHRMa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)